Zobrazeno 1 - 10
of 194
pro vyhledávání: '"Donald P Lawrence"'
Autor:
Mariano Severgnini, Rizwan Haq, Anita Giobbie-Hurder, Scott J Rodig, Patrick A Ott, Evisa Gjini, Ryan J Sullivan, Donald P Lawrence, Matthew Nazzaro, Kathleen L Pfaff, Jacquelyn O Wolff, Elizabeth I Buchbinder
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/209a1d9fbce1433f83f364f311d116e0
Autor:
F Stephen Hodi, Ahmad A Tarhini, John M Kirkwood, Zeynep Eroglu, Henry B Koon, Ni Kang, Vernon K Sondak, Harriet M Kluger, Sandra J Lee, Gary I Cohen, Laura F Hutchins, Donald P Lawrence, Kari L Kendra, David R Minor, Carrie B Lee, Mark R Albertini, Lawrence E Flaherty, Teresa M Petrella
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background The impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood.Patients and method
Externí odkaz:
https://doaj.org/article/6f596cfb2e7048f7b2e60a6a21991735
Autor:
Adam A Friedman, Arnaud Amzallag, Iulian Pruteanu-Malinici, Subash Baniya, Zachary A Cooper, Adriano Piris, Leeza Hargreaves, Vivien Igras, Dennie T Frederick, Donald P Lawrence, Daniel A Haber, Keith T Flaherty, Jennifer A Wargo, Sridhar Ramaswamy, Cyril H Benes, David E Fisher
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140310 (2015)
A newer generation of anti-cancer drugs targeting underlying somatic genetic driver events have resulted in high single-agent or single-pathway response rates in selected patients, but few patients achieve complete responses and a sizeable fraction o
Externí odkaz:
https://doaj.org/article/2c65cc61a9ae4bf8a9a2e40f9c38d289
Autor:
John C Morris, Antoinette R Tan, Thomas E Olencki, Geoffrey I Shapiro, Bruce J Dezube, Michael Reiss, Frank J Hsu, Jay A Berzofsky, Donald P Lawrence
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90353 (2014)
In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. Here, the safety and ac
Externí odkaz:
https://doaj.org/article/0353ebcc11b249188233f547e8275d23
Autor:
Meghan J. Mooradian, James M. Cleary, Anita Giobbie‐Hurder, Lancia N. F. Darville, Aparna Parikh, Elizabeth I. Buchbinder, Justine V. Cohen, Donald P. Lawrence, Geoffrey I. Shapiro, Harold Keer, Helen X. Chen, Susan Percy Ivy, Keiran S. M. Smalley, John M. Koomen, Ryan J. Sullivan
Publikováno v:
Cancer. 129:1904-1918
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2ec6bc2b1f70e58acff9eae9363547a
https://doi.org/10.1002/cncr.34730
https://doi.org/10.1002/cncr.34730
Autor:
Xue Bai, Alexander N. Shoushtari, Allison Betof Warner, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Henry T. Quach, Christopher G. Cann, Michael Z. Zhang, Lalit Pallan, Catriona Harvey, Michelle S. Kim, Gyulnara Kasumova, Tatyana Sharova, Justine V. Cohen, Donald P. Lawrence, Christine Freedman, Riley M. Fadden, Krista M. Rubin, Dennie T. Frederick, Keith T. Flaherty, Georgina V. Long, Alexander M. Menzies, Ryan J. Sullivan, Genevieve M. Boland, Douglas B. Johnson, Jun Guo
Publikováno v:
British Journal of Dermatology. 187:401-410
Background Programmed cell death receptor-1 (PD-1) monotherapy is a standard treatment for advanced cutaneous melanoma, but its efficacy and toxicity are defined in white populations and remain poorly characterized in other ethnic groups, such as Eas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16b54bf322584116eb6234c0ecff983d
https://doi.org/10.1111/bjd.21241
https://doi.org/10.1111/bjd.21241
Autor:
Levi A. Garraway, Jennifer A. Wargo, Keith T. Flaherty, Scott L. Carter, Stacey B. Gabriel, Gad Getz, Sheila Fisher, Donald P. Lawrence, Eran Hodis, Gregory Kryukov, Kristian Cibulskis, Aaron McKenna, Cory M. Johannessen, Danielle Perrin, Kristin Anderka, Dennis C. Friedrich, Deborah N. Farlow, Ryan J. Sullivan, Eva M. Goetz, Mara Rosenberg, Amaro Taylor-Weiner, Zachary A. Cooper, Dennie T. Frederick, Daniel J. Treacy, Eliezer M. Van Allen, Nikhil Wagle
XLSX file 3569K, Change in Cancer Cell Fraction for all SNVs and Indels in All Samples
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2deea5c2c969e4a862f7cb47d2a497f3
https://doi.org/10.1158/2159-8290.22530000
https://doi.org/10.1158/2159-8290.22530000
Autor:
Levi A. Garraway, Jennifer A. Wargo, Keith T. Flaherty, Scott L. Carter, Stacey B. Gabriel, Gad Getz, Sheila Fisher, Donald P. Lawrence, Eran Hodis, Gregory Kryukov, Kristian Cibulskis, Aaron McKenna, Cory M. Johannessen, Danielle Perrin, Kristin Anderka, Dennis C. Friedrich, Deborah N. Farlow, Ryan J. Sullivan, Eva M. Goetz, Mara Rosenberg, Amaro Taylor-Weiner, Zachary A. Cooper, Dennie T. Frederick, Daniel J. Treacy, Eliezer M. Van Allen, Nikhil Wagle
XLSX file 31K, Coverage and Metrics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28bdf7aa0f8c302cf82e86bc6c35fda4
https://doi.org/10.1158/2159-8290.22529985
https://doi.org/10.1158/2159-8290.22529985
Autor:
Levi A. Garraway, Jennifer A. Wargo, Keith T. Flaherty, Scott L. Carter, Stacey B. Gabriel, Gad Getz, Sheila Fisher, Donald P. Lawrence, Eran Hodis, Gregory Kryukov, Kristian Cibulskis, Aaron McKenna, Cory M. Johannessen, Danielle Perrin, Kristin Anderka, Dennis C. Friedrich, Deborah N. Farlow, Ryan J. Sullivan, Eva M. Goetz, Mara Rosenberg, Amaro Taylor-Weiner, Zachary A. Cooper, Dennie T. Frederick, Daniel J. Treacy, Eliezer M. Van Allen, Nikhil Wagle
XLSX file 12K, Candidate Resistance Genes from RNAi and ORF Functional Screens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15fc1641bea27ab1f28a5d67a4da4a49
https://doi.org/10.1158/2159-8290.22529991
https://doi.org/10.1158/2159-8290.22529991
Autor:
Ryan J. Sullivan, James W. Mier, Keith T. Flaherty, A. John Iafrate, Michael B. Atkins, Dennie Fredrick, Anasuya Gunturi, F. Stephen Hodi, Virginia J. Seery, Ryan Merritt, Jennifer A. Wargo, Alexander Carlson, Rachel Cohen, David F. McDermott, Donald P. Lawrence, Alireza Sepehr, Laleh Montaser-Kouhsari, Aislyn P. Schalck, Anita Giobbie-Hurder, Elizabeth Buchbinder, David J. Panka
BRAF inhibitors (BRAFi) have led to clinical benefit in patients with melanoma. The development of a blood-based assay to detect and quantify BRAF levels in these patients has diagnostic, prognostic, and predictive capabilities that could guide treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e4fef1a26720d8b3344d7e0a2a2f162
https://doi.org/10.1158/1535-7163.c.6536487
https://doi.org/10.1158/1535-7163.c.6536487